Rezolute to Participate in Upcoming Investor Conferences in September
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage
biopharmaceutical company dedicated to developing transformative
therapies with the potential to disrupt current treatment paradigms
for devastating metabolic diseases, today announced that Nevan
Charles Elam, Chief Executive Officer and Founder, will participate
in two upcoming investor conferences.
- H.C. Wainwright
25th Annual Global Investment Conference taking place September
11-13, 2023 in New York, New York – Company presentation on
Tuesday, September 12, 2023 at 2:00 p.m. ET
Fitzgerald Global Healthcare Conference taking place September
26-28, 2023 in New York, New York – Panel presentation on Tuesday,
September 26, 2023 at 2:10 p.m. ET
Live webcasts will be available under "Events"
in the Investor section of the Company's website at
https://ir.rezolutebio.com/news-events/ir-calendar. A replay will
be archived for 90 days following the presentation date.
About Rezolute, Inc.Rezolute
strives to disrupt current treatment paradigms by developing
transformative therapies for devastating rare and chronic metabolic
diseases. Its novel therapies hold the potential to both
significantly improve outcomes and reduce the treatment burden for
patients, the treating physician, and the healthcare system.
Patient, clinician, and advocate voices are integrated in the
Company’s drug development process, enabling Rezolute to boldly
address a range of severe conditions. Rezolute is steadfast in its
mission to create profound, positive, and lasting impact on
patients’ lives. The Company’s lead clinical asset, RZ358, is in
late-stage development for the treatment of congenital
hyperinsulinism, a rare pediatric endocrine disorder. Rezolute is
also developing RZ402, an orally available plasma kallikrein
inhibitor, for the treatment of diabetic macular edema. For more
information, visit www.rezolutebio.com or follow us on
Twitter or LinkedIn.
information provided herein contain "forward-looking statements"
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on Rezolute’s current
beliefs, expectations and assumptions regarding the future of its
businesses, results of and timing of clinical trials, financial
condition and results of operations, future plans and strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of Rezolute’s control. Rezolute’s actual results
including the timing and results of clinical trials may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not place undue reliance on any of these
forward-looking statements. Important factors that could cause
Rezolute’s actual results including the timing and results of
clinical trials to differ materially from those indicated in the
forward-looking statements are discussed or identified in
Rezolute’s filings made with the U.S. Securities and Exchange
Commission. Any forward-looking statements made by Rezolute in this
information are based only on information currently available to
Rezolute and speak only as of the date on which the statement is
made. Rezolute undertakes no obligation to update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise except as required by applicable
Historical Stock Chart
From Nov 2023 to Dec 2023
Historical Stock Chart
From Dec 2022 to Dec 2023